Interpace Biosciences (IDXG) Misses Q2 EPS by 41c

Interpace Biosciences (OTC: IDXG) reported Q2 EPS of ($0.93), $0.41 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Piper Sandler's Weekly Focus Idea: Principal Financial Group (PFG)
• Tesla Q2 deliveries: What to expect from the critical report